M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

Recruiting

Conditions: Patient
Caregiver

Interventions: Other: Survey Administration

First Posted Date: 2019-10-16

Last Posted Date: 2024-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 400

Registration Number: NCT04129138

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families

Not Applicable

Active, not recruiting

Conditions: Hereditary Ovarian Carcinoma
Hereditary Breast Carcinoma
Lynch Syndrome

Interventions: Behavioral: Behavioral Dietary Intervention
Other: E-mail
Behavioral: Exercise Intervention
Other: Health Promotion and Education
Other: Internet-Based Intervention
Other: Questionnaire Administration
Behavioral: Telephone-Based Intervention

First Posted Date: 2019-10-14

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 384

Registration Number: NCT04125914

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cordotomy in Reducing Pain in Patients With Advanced Cancer

Not Applicable

Recruiting

Conditions: Advanced Malignant Neoplasm

Interventions: Procedure: Cordotomy
Drug: Morphine
Other: Questionnaire Administration
Procedure: Sham Intervention

First Posted Date: 2019-10-08

Last Posted Date: 2024-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT04119037

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2

Withdrawn

Conditions: Locally Advanced Adrenal Gland Pheochromocytoma
Locally Advanced Paraganglioma
Metastatic Adrenal Gland Pheochromocytoma
Metastatic Paraganglioma
Metastatic Parathyroid Gland Carcinoma
Pituitary Gland Carcinoma
Unresectable Adrenal Gland Pheochromocytoma
Somatostatin Receptor Positive
Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8

Interventions: Drug: Lutetium Lu 177 Dotatate

First Posted Date: 2019-09-27

Last Posted Date: 2020-09-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04106843

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of EHealth Coaching Program on Patient Reported Outcomes of Men With Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Carcinoma

Interventions: Behavioral: Behavioral Intervention
Other: Survey Administration

First Posted Date: 2019-09-26

Last Posted Date: 2023-08-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 145

Registration Number: NCT04106245

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2

Recruiting

Conditions: Anatomic Stage IIIA Breast Cancer AJCC v8
Germline BRCA1 Gene Mutation
Germline BRCA2 Gene Mutation
HER2/Neu Negative
Metastatic Breast Carcinoma
Prognostic Stage III Breast Cancer AJCC v8
Advanced Breast Carcinoma
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8

Interventions: Drug: Cediranib
Drug: Ceralasertib
Drug: Olaparib

First Posted Date: 2019-09-16

Last Posted Date: 2024-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04090567

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Recurrent Leukemia
Advanced Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Caregiver
Recurrent Lymphoma
Recurrent Plasma Cell Myeloma

First Posted Date: 2019-09-16

Last Posted Date: 2024-01-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 192

Registration Number: NCT04090619

Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer

Completed

Conditions: Invasive Breast Carcinoma

Interventions: Other: Interview
Other: Medical Chart Review
Behavioral: Questionnaire

First Posted Date: 2019-09-12

Last Posted Date: 2024-04-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT04087057

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

Phase 3

Active, not recruiting

Conditions: Malignant Liver Neoplasm

Interventions: Procedure: Ablation Therapy
Other: Quality-of-Life Assessment
Procedure: Image-Guided Therapy
Other: Questionnaire Administration

First Posted Date: 2019-09-10

Last Posted Date: 2024-10-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT04083378

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

Phase 2

Completed

Conditions: Locally Advanced Malignant Solid Neoplasm

Interventions: Biological: Pembrolizumab

First Posted Date: 2019-09-09

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT04082572

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy